Alaunos Therapeutics (TCRT) Free Cash Flow (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Free Cash Flow came in at -$1.0 million in Q1 2026, down 33.55% YoY from -$1.6 million in Q1 2025, and down 86.44% on a QoQ basis from -$553000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Free Cash Flow (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Free Cash Flow data on file, last reported at -$1.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 33.55% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.1 million (up 18.22% YoY) and the FY2025 annual result came in at -$3.0 million, up 40.31% from the prior year.
- Free Cash Flow eased to -$1.0 million in Q1 2026, from -$553000.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$553000.0 in Q4 2025 to a low of -$9.5 million in Q1 2023.
- A 5-year average of -$4.0 million and a median of -$1.9 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow surged 91.98% — and 2026, when it tumbled 33.55%.
- Tracing TCRT's Free Cash Flow over 5 years: stood at -$7.4 million in 2022, then retreated by 0.45% to -$7.4 million in 2023, then surged by 91.98% to -$592000.0 in 2024, then advanced by 6.59% to -$553000.0 in 2025, then plunged by 86.44% to -$1.0 million in 2026.
- The last three Free Cash Flow figures came in at -$1.0 million (Q1 2026), -$553000.0 (Q4 2025), and -$844000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | -300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | -553,000.00 |
| Dec 31, 2025 | -553,000.00 |
| Sep 30, 2025 | -844,000.00 |
| Sep 30, 2025 | -844,000.00 |
| Jun 30, 2025 | -701,000.00 |
| Jun 30, 2025 | -701,000.00 |
| Mar 31, 2025 | -772,000.00 |
| Mar 31, 2025 | -772,000.00 |
| Dec 31, 2024 | -592,000.00 |
| Dec 31, 2024 | -592,000.00 |
| Sep 30, 2024 | -781,000.00 |
| Sep 30, 2024 | -781,000.00 |
| Jun 30, 2024 | -1.68 Mn |
| Jun 30, 2024 | -1.68 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Dec 31, 2023 | -7.39 Mn |
| Dec 31, 2023 | -7.39 Mn |